Lung Preservation Device Could Increase Donor Pool
By HospiMedica International staff writers Posted on 25 Aug 2014 |
Image: The XVIVO XPS Lung Preservation Device (Photo courtesy of XVIVO Perfusion).
A novel device for preserving donated lungs that do not initially meet the standard criteria for transplantation may result in more availability.
The XVIVO Perfusion System (XPS) is fully integrated off-the-shelf cardiac bypass system which includes a centrifugal pump, a heater/cooler unit, and a ventilator. The system works by mimicking in vivo conditions, flushing and temporarily preserving continuous normothermic perfusion of initially unacceptable excised donor lungs for up to four hours. During this time, the function of the lungs can be reevaluated and assessed for viability as a transplantable organ. If they meet functionality criteria, and pass the transplant surgeon examination, the lungs are transplanted into a recipient.
The ventilated lung is perfused with a 15% deoxygenated suspension of red blood cells (RBCs) in STEEN Solution while critical parameters of gaseous exchange, pulmonary vascular resistance, and other key variables under normothermic conditions are monitored. The XPS also ventilates the lungs, which oxygenates the cells and makes it possible for the transplant team to examine the airways with a bronchoscope. The XVIVO Perfusion System is a product of XVIVO Perfusion (Englewood, CO, USA), and has been approved by the US Food and Drug Administration (FDA).
“This innovative device addresses a critical public health need,” said Christy Foreman, director of the office of device evaluation at the FDA Center for Devices and Radiological Health (CDRH). “With this approval, there may be more lungs available for transplant, which could allow more people with end stage lung disease who have exhausted all other treatment options to be able to receive a lung transplant.”
Lung transplantation is a primary option in the care of patients with end-stage chronic lung diseases, such as chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and idiopathic pulmonary fibrosis. Approximately one in five donated lungs meets the standard criteria for a donor lung and is transplanted into a recipient. In 2012, 1,754 lung transplants were performed in the United States alone; at the same time, 1,616 potential recipients remained on the waiting list.
STEEN Solution contains human serum albumin to provide normal oncotic pressure, preventing edema formation; dextran, a mild scavenger which coats and protects endothelium from subsequent excessive leucocyte interaction and thrombogenesis; and an extra-cellular electrolyte composition (lowK +) that reduces free radical generation and avoids vascular spasm under normothermic conditions.
Related Links:
XVIVO Perfusion
The XVIVO Perfusion System (XPS) is fully integrated off-the-shelf cardiac bypass system which includes a centrifugal pump, a heater/cooler unit, and a ventilator. The system works by mimicking in vivo conditions, flushing and temporarily preserving continuous normothermic perfusion of initially unacceptable excised donor lungs for up to four hours. During this time, the function of the lungs can be reevaluated and assessed for viability as a transplantable organ. If they meet functionality criteria, and pass the transplant surgeon examination, the lungs are transplanted into a recipient.
The ventilated lung is perfused with a 15% deoxygenated suspension of red blood cells (RBCs) in STEEN Solution while critical parameters of gaseous exchange, pulmonary vascular resistance, and other key variables under normothermic conditions are monitored. The XPS also ventilates the lungs, which oxygenates the cells and makes it possible for the transplant team to examine the airways with a bronchoscope. The XVIVO Perfusion System is a product of XVIVO Perfusion (Englewood, CO, USA), and has been approved by the US Food and Drug Administration (FDA).
“This innovative device addresses a critical public health need,” said Christy Foreman, director of the office of device evaluation at the FDA Center for Devices and Radiological Health (CDRH). “With this approval, there may be more lungs available for transplant, which could allow more people with end stage lung disease who have exhausted all other treatment options to be able to receive a lung transplant.”
Lung transplantation is a primary option in the care of patients with end-stage chronic lung diseases, such as chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and idiopathic pulmonary fibrosis. Approximately one in five donated lungs meets the standard criteria for a donor lung and is transplanted into a recipient. In 2012, 1,754 lung transplants were performed in the United States alone; at the same time, 1,616 potential recipients remained on the waiting list.
STEEN Solution contains human serum albumin to provide normal oncotic pressure, preventing edema formation; dextran, a mild scavenger which coats and protects endothelium from subsequent excessive leucocyte interaction and thrombogenesis; and an extra-cellular electrolyte composition (lowK +) that reduces free radical generation and avoids vascular spasm under normothermic conditions.
Related Links:
XVIVO Perfusion
Latest Surgical Techniques News
- Miniaturized Implantable Multi-Sensors Device to Monitor Vessels Health
- Tiny Robots Made Out Of Carbon Could Conduct Colonoscopy, Pelvic Exam or Blood Test
- Miniaturized Ultrasonic Scalpel Enables Faster and Safer Robotic-Assisted Surgery
- AI Assisted Reading Tool for Small Bowel Video Capsule Endoscopy Detects More Lesions
- First-Ever Contact Force Pulsed Field Ablation System to Transform Treatment of Ventricular Arrhythmias
- Caterpillar Robot with Built-In Steering System Crawls Easily Through Loops and Bends
- Tiny Wraparound Electronic Implants to Revolutionize Treatment of Spinal Cord Injuries
- Small, Implantable Cardiac Pump to Help Children Awaiting Heart Transplant
- Gastrointestinal Imaging Capsule a Game-Changer in Esophagus Surveillance and Treatment
- World’s Smallest Laser Probe for Brain Procedures Facilitates Ablation of Full Range of Targets
- Artificial Intelligence Broadens Diagnostic Abilities of Conventional Coronary Angiography
- AI-Powered Surgical Visualization Tool Supports Surgeons' Visual Recognition in Real Time
- Cutting-Edge Robotic Bronchial Endoscopic System Provides Prompt Intervention during Emergencies
- Handheld Device for Fluorescence-Guided Surgery a Game Changer for Removal of High-Grade Glioma Brain Tumors
- Porous Gel Sponge Facilitates Rapid Hemostasis and Wound Healing
- Novel Rigid Endoscope System Enables Deep Tissue Imaging During Surgery